New powdered plasma shows promise in early safety trial
NCT ID NCT05629338
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested the safety of a new spray-dried plasma product called FrontlineODP in 24 healthy volunteers. Participants received increasing doses (1 to 4 units) to see if it causes side effects. The goal is to develop a shelf-stable plasma that can be stored at room temperature for emergency bleeding situations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Spray-dried plasma (FrontlineODP)
What this could lead to
If safe, this could lead to a shelf-stable plasma product for treating bleeding in emergencies, especially where fresh plasma is unavailable.
What could go wrong
This is a very early Phase 1 safety study in only 24 healthy people, not patients. It does not test effectiveness, and side effects may still emerge.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoxworth Blood Center
Cincinnati, Ohio, 45267-0055, United States
-
Spaulding Clinical Research LLC
West Bend, Wisconsin, 53095, United States
-
Versiti Blood Center of Wisconsin
Milwaukee, Wisconsin, 53233, United States